Flowers are budding and temperatures are rising, which can only mean one thing: allergy season is upon us.
Several states including Illinois, North Carolina and Tennessee are already reporting increases in patients complaining of itching, watering eyes, sneezing and coughing.
Meteorologists are predicting that 2019 may be the worst year ever for allergies and the culprit is pollen.
Pollen counts have been rising across the country and, according to the National Allergy Map, half the country is experiencing high levels, much earlier than usual for this time of year.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.